{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T11:29:07Z","timestamp":1790422147356,"version":"4.1.0"},"reference-count":30,"publisher":"Oxford University Press (OUP)","issue":"11","license":[{"start":{"date-parts":[[2022,4,26]],"date-time":"2022-04-26T00:00:00Z","timestamp":1650931200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"DOI":"10.13039\/100001797","name":"PhRMA Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001797","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000865","name":"Bill and Melinda Gates Foundation","doi-asserted-by":"publisher","award":["OPP1099837"],"award-info":[{"award-number":["OPP1099837"]}],"id":[{"id":"10.13039\/100000865","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005595","name":"University of California","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005595","id-type":"DOI","asserted-by":"publisher"}]},{"name":"The Fulbright U.S. Scholar Program"},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005564","name":"Gilead Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005564","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,11,30]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Daily dosing of tenofovir disoproxil fumarate, with or without emtricitabine, has high efficacy in preventing human immunodeficiency virus (HIV) infection when individuals are adherent. The target protective plasma concentration of tenofovir (TFV), however, is not fully understood. The aim of this study is to estimate the protective TFV plasma concentration.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Participant data from TFV-based daily oral and topical active arms of phase 3 trials (iPrEx, VOICE, and Partners PrEP) were pooled (n = 2950). Individual specific risk scores (low and high risk) of acquiring HIV, based on an earlier placebo analysis, were created. Longitudinal TFV pharmacokinetics (PK), HIV outcome, individual risk scores and the effect of sex at birth data were integrated and analyzed using non-linear mixed effects models.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Around 50% of the individuals were estimated to be adherent, which differed from self-reported adherence (\u223c90%) and large variation between longitudinal adherence patterns were identified. Following oral administration, the estimated protective TFV trough concentration was substantially higher in high-risk females (45.8\u2005ng\/mL) compared with high-risk males (16.1\u2005ng\/mL) and to low-risk individuals (\u223c7.5\u2005ng\/mL). Dosing simulations indicated that high-risk women require full adherence to maintain protective levels.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Using the largest PK-HIV outcome database to date, we developed a population adherence-PK-risk-outcome model. Our results indicate that high-risk females need higher levels of plasma TFV to achieve HIV protection compared with males. HIV protection exceeds 90% in all populations if daily adherence is achieved.<\/jats:p><\/jats:sec>","DOI":"10.1093\/cid\/ciac313","type":"journal-article","created":{"date-parts":[[2022,4,25]],"date-time":"2022-04-25T19:11:18Z","timestamp":1650913878000},"page":"1873-1882","source":"Crossref","is-referenced-by-count":22,"title":["Characterizing HIV-Preventive, Plasma Tenofovir Concentrations\u2014A Pooled Participant-level Data Analysis From Human Immunodeficiency Virus Preexposure Prophylaxis Clinical Trials"],"prefix":"10.1093","volume":"75","author":[{"given":"Maria","family":"Garcia-Cremades","sequence":"first","affiliation":[{"name":"Department of Bioengineering and Therapeutic Sciences, University of California San Francisco , San Francisco, California , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katarina","family":"Vu\u010di\u0107evi\u0107","sequence":"additional","affiliation":[{"name":"Department of Bioengineering and Therapeutic Sciences, University of California San Francisco , San Francisco, California , USA"},{"name":"Department of Pharmacokinetics and Clinical Pharmacy, University of Belgrade-Faculty of Pharmacy , Belgrade , Serbia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Craig W","family":"Hendrix","sequence":"additional","affiliation":[{"name":"Division of Clinical Pharmacology, Department of Medicine, Johns Hopkins University , Baltimore, Maryland , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Priya","family":"Jayachandran","sequence":"additional","affiliation":[{"name":"Department of Bioengineering and Therapeutic Sciences, University of California San Francisco , San Francisco, California , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leah","family":"Jarlsberg","sequence":"additional","affiliation":[{"name":"Department of Bioengineering and Therapeutic Sciences, University of California San Francisco , San Francisco, California , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Grant","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of California San Francisco , San Francisco, California , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Connie L","family":"Celum","sequence":"additional","affiliation":[{"name":"Departments of Global Health, Medicine, and Epidemiology, University of Washington , Seattle, Washington , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Martin","sequence":"additional","affiliation":[{"name":"Centers for Disease Control and Prevention, National Center For HIV\/AIDS, Viral Hepatitis, STD, and TB Prevention, Division of HIV\/AIDS Prevention , Atlanta, Georgia , USA"},{"name":"Thailand Ministry of Public Health-US CDC Collaboration , Nonthaburi , Thailand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jared M","family":"Baeten","sequence":"additional","affiliation":[{"name":"Departments of Global Health, Medicine, and Epidemiology, University of Washington , Seattle, Washington , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeanne","family":"Marrazzo","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, University of Alabama at Birmingham Medical Center , Birmingham, Alabama , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Anderson","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Sciences, University of Colorado , Denver, Colorado , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kachit","family":"Choopanya","sequence":"additional","affiliation":[{"name":"Bangkok Tenofovir Study Group , Bangkok , Thailand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suphak","family":"Vanichseni","sequence":"additional","affiliation":[{"name":"Bangkok Tenofovir Study Group , Bangkok , Thailand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David V","family":"Glidden","sequence":"additional","affiliation":[{"name":"Department of Epidemiology and Biostatistics, University of California San Francisco , San Francisco, California , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Radojka M","family":"Savic","sequence":"additional","affiliation":[{"name":"Department of Bioengineering and Therapeutic Sciences, University of California San Francisco , San Francisco, California , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2022,4,26]]},"reference":[{"key":"2023053018560129500_ciac313-B1","volume-title":"HIV\/AIDS fact sheet","author":"WHO"},{"key":"2023053018560129500_ciac313-B2","doi-asserted-by":"crossref","first-page":"2587","DOI":"10.1056\/NEJMoa1011205","article-title":"Preexposure chemoprophylaxis for HIV prevention in men who have sex with men","volume":"363","author":"Grant","year":"2010","journal-title":"N Engl J Med"},{"key":"2023053018560129500_ciac313-B3","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1056\/NEJMoa1402269","article-title":"Tenofovir-based preexposure prophylaxis for HIV infection among African women","volume":"372","author":"Marrazzo","year":"2015","journal-title":"N Engl J Med"},{"key":"2023053018560129500_ciac313-B4","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1056\/NEJMoa1108524","article-title":"Antiretroviral prophylaxis for HIV prevention in heterosexual men and women","volume":"367","author":"Baeten","year":"2012","journal-title":"N Engl J Med"},{"key":"2023053018560129500_ciac313-B5","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1056\/NEJMoa1110711","article-title":"Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana","volume":"367","author":"Thigpen","year":"2012","journal-title":"N Engl J Med"},{"key":"2023053018560129500_ciac313-B6","doi-asserted-by":"crossref","first-page":"2083","DOI":"10.1016\/S0140-6736(13)61127-7","article-title":"Antiretroviral prophylaxis for HIV infection in injecting drug users in Bangkok. Thailand (the Bangkok Tenofovir Study): a randomised, double-blind, placebo-controlled phase 3 trial","volume":"381","author":"Choopanya","year":"2013","journal-title":"Lancet"},{"key":"2023053018560129500_ciac313-B7","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1126\/science.1193748","article-title":"Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women","volume":"329","author":"Karim","year":"2010","journal-title":"Science"},{"key":"2023053018560129500_ciac313-B8","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1056\/NEJMoa1202614","article-title":"Preexposure prophylaxis for HIV infection among African women","volume":"367","author":"Van Damme","year":"2012","journal-title":"N Engl J Med"},{"key":"2023053018560129500_ciac313-B9","doi-asserted-by":"crossref","first-page":"S55","DOI":"10.1093\/cid\/ciu266","article-title":"Adherence to preexposure prophylaxis: current, emerging, and anticipated bases of evidence","volume":"9","author":"Amico","year":"2014","journal-title":"Clin Infect Dis"},{"key":"2023053018560129500_ciac313-B10","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1089\/apc.2014.0195","article-title":"Medication adherence among men who have sex with men at risk for HIV infection in the United States: implications for pre-exposure prophylaxis implementation","volume":"28","author":"Liu","year":"2014","journal-title":"AIDS Patient Care STDS"},{"key":"2023053018560129500_ciac313-B11","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1089\/apc.2009.0081","article-title":"Early patterns of adherence in adolescents initiating highly active antiretrovial therapy predict long-term adherence, virologic, and immunologic control","volume":"23","author":"Lindsey","year":"2009","journal-title":"AIDS Patient Care STDS"},{"key":"2023053018560129500_ciac313-B12","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1089\/apc.2009.0198","article-title":"Prevalence and interactions of patient-related risks for nonadherence to antiretroviral therapy among perinatally infected youth in the United States","volume":"24","author":"Rudy","year":"2010","journal-title":"AIDS Patient Care STDS"},{"key":"2023053018560129500_ciac313-B13","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1001\/archpedi.159.8.764","article-title":"Longitudinal antiretroviral adherence among adolescents infected with human immunodeficiency virus","volume":"159","author":"Murphy","year":"2005","journal-title":"Arch Pediatr Adolesc Med"},{"key":"2023053018560129500_ciac313-B14","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1097\/QAI.0b013e3182801081","article-title":"The acceptability and feasibility of an HIV preexposure prophylaxis (PrEP) trial with young men who have sex with men","volume":"62","author":"Hosek","year":"2013","journal-title":"J Acquir Immune Defic Syndr"},{"key":"2023053018560129500_ciac313-B15","doi-asserted-by":"crossref","first-page":"2237","DOI":"10.1056\/NEJMoa1506273","article-title":"On-demand preexposure prophylaxis in men at high risk for HIV-1 infection","volume":"373","author":"Molina","year":"2015","journal-title":"N Engl J Med"},{"key":"2023053018560129500_ciac313-B16","first-page":"128","volume-title":"NONMEM users guide: introduction to NONMEM 7.4.1","author":"Bauer","year":"2017"},{"key":"2023053018560129500_ciac313-B17","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1007\/s10928-008-9094-4","article-title":"Likelihood based approaches to handling data below the quantification limit using NONMEM VI","volume":"35","author":"Ahn","year":"2008","journal-title":"J Pharmacokinet Pharmacodyn"},{"key":"2023053018560129500_ciac313-B18","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1023\/A:1011582713692","article-title":"Selecting reliable pharmacokinetic data for explanatory analyses of clinical trials in the presence of possible noncompliance","volume":"28","author":"Lu","year":"2001","journal-title":"J Pharmacokinet Pharmacodyn"},{"key":"2023053018560129500_ciac313-B19","article-title":"Modelling survival data in medical research","author":"Collett","year":"1952"},{"key":"2023053018560129500_ciac313-B20","doi-asserted-by":"crossref","first-page":"e43","DOI":"10.1038\/psp.2013.18","article-title":"A time to event tutorial for pharmacometricians","volume":"2","author":"Holford","year":"2013","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"key":"2023053018560129500_ciac313-B21","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1097\/QAI.0000000000000172","article-title":"HIV protective efficacy and correlates of tenofovir blood concentrations in a clinical trial of PrEP for HIV prevention","volume":"66","author":"Donnell","year":"2014","journal-title":"J Acquir Immune Defic Syndr"},{"key":"2023053018560129500_ciac313-B22","doi-asserted-by":"crossref","first-page":"1990","DOI":"10.1056\/NEJMsb1708278","article-title":"Data sharing from clinical trials\u2014a research funder\u2019s perspective","volume":"377","author":"Kiley","year":"2017","journal-title":"N Engl J Med"},{"key":"2023053018560129500_ciac313-B23","doi-asserted-by":"crossref","first-page":"e28","DOI":"10.1371\/journal.pmed.0050028","article-title":"Prevention of rectal SHIV transmission in macaques by daily or intermittent prophylaxis with emtricitabine and tenofovir","volume":"5","author":"Garc\u00eda-Lerma","year":"2008","journal-title":"PLoS Med"},{"key":"2023053018560129500_ciac313-B24","doi-asserted-by":"crossref","first-page":"112re4","DOI":"10.1126\/scitranslmed.3003174","article-title":"Penetration of tenofovir and emtricitabine in mucosal tissues: implications for prevention of HIV-1 transmission","volume":"3","author":"Patterson","year":"2011","journal-title":"Sci Transl Med"},{"key":"2023053018560129500_ciac313-B25","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1016\/j.cell.2013.09.030","article-title":"Exploring concentration response in HIV pre-exposure prophylaxis to optimize clinical care and trial design","volume":"155","author":"Hendrix","year":"2013","journal-title":"Cell"},{"issue":"Suppl 4","key":"2023053018560129500_ciac313-B26","doi-asserted-by":"crossref","first-page":"e25298","DOI":"10.1002\/jia2.25298","article-title":"HIV pre-exposure prophylaxis for adolescent girls and young women in Africa: from efficacy trials to delivery","volume":"22","author":"Celum","year":"2019","journal-title":"J Int AIDS Soc"},{"key":"2023053018560129500_ciac313-B27","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1126\/science.aai9383","article-title":"Vaginal bacteria modify HIV tenofovir microbicide efficacy in African women","volume":"356","author":"Klatt","year":"2017","journal-title":"Science"},{"key":"2023053018560129500_ciac313-B28","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1097\/QAI.0000000000000301","article-title":"GSK1265744 pharmacokinetics in plasma and tissue after single-dose long-acting injectable administration in healthy subjects","volume":"67","author":"Spreen","year":"2014","journal-title":"J Acquir Immune Defic Syndr"},{"key":"2023053018560129500_ciac313-B29","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.1093\/jac\/dkx064","article-title":"Single-dose pharmacokinetics of tenofovir alafenamide and its active metabolite in the mucosal tissues","volume":"72","author":"Cottrell","year":"2017","journal-title":"J Antimicrob Chemother"},{"issue":"10246","key":"2023053018560129500_ciac313-B30","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/S0140-6736(20)31065-5","article-title":"Emtricitabine and tenofovir alafenamide vs emtricitabine and tenofovir disoproxil fumarate for HIV pre-exposure prophylaxis (DISCOVER): primary results from a randomised, double-blind, multicentre, active-controlled, phase 3, non-inferiority trial","volume":"396","author":"Mayer","year":"2020","journal-title":"Lancet"}],"container-title":["Clinical Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/cid\/advance-article-pdf\/doi\/10.1093\/cid\/ciac313\/44282153\/ciac313.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cid\/article-pdf\/75\/11\/1873\/50490923\/ciac313.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cid\/article-pdf\/75\/11\/1873\/50490923\/ciac313.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,20]],"date-time":"2023-11-20T15:37:24Z","timestamp":1700494644000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/cid\/article\/75\/11\/1873\/6574602"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,26]]},"references-count":30,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2022,4,26]]},"published-print":{"date-parts":[[2022,11,30]]}},"URL":"https:\/\/doi.org\/10.1093\/cid\/ciac313","relation":{},"ISSN":["1058-4838","1537-6591"],"issn-type":[{"value":"1058-4838","type":"print"},{"value":"1537-6591","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,12,1]]},"published":{"date-parts":[[2022,4,26]]}}}